Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple...